NCT00423410已完成1 期
A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas
EpiCept Corporation3 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Safety
研究概览
简要总结
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not responded to or have recurred following treatment with available therapies
详细描述
This is a Phase I, open label, multicenter, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of EPC2407 administered intravenously over 60 minutes on a QDx3 schedule repeated every 21 days. Patients are enrolled and dosed at the level defined by the escalation scheme. The primary goal of the study design is to assess toxicity at the fixed dose levels according to the modified Fibonacci schema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed solid tumor or lymphoma,which has progressed on standard therapies, for which effective therapy is not available or for patients who are unwilling to undergo such therapies.
- •Males and Females at least 18 years of age
- •Laboratory data as specified below (according to the site's clinical laboratory ranges for normal):
- •i. Hematology: ANC >1500 cells/mm3, platelet count >100,000 cells/mm3 and Hemoglobin > 9 gm/L ii. Hepatic: Direct bilirubin <1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. For patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN iii. Renal: serum creatinine WNL or creatinine clearance >60 mL/min
- •12-lead electrocardiogram (ECG) QT intervals: QTc ≤ 450 msec for men and ≤ 470 msec for women.
- •Estimated life expectancy of at least 3 months
- •ECOG Performance Status < or = 1
- •Previously treated CNS disease allowed if treatment completed and stable for 4 weeks.
- •For men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments
- •Cardiac ejection fraction ≥50% by 2D Echocardiogram or > institutional lower limits of normal
排除标准
- •Women who are pregnant or nursing
- •Radiotherapy or any chemotherapy within the previous 21 days or five half lives of prior drug (whichever is shorter). See also exclusion #4 below for patients at risk for cardiac toxicity. Recovery to Grade 1 or less from chemotherapy-induced toxic effect, except alopecia, is required.
- •Major surgery within the last 4 weeks or minor surgery within the last 2 weeks
- •Significant risk of cardiac drug toxicity due to any of the following: a) Active New York Heart Association Class III or IV, b) history of or current congestive heart failure, c) history of myocardial infarction within the last 6 months or ongoing unstable angina, or anthracycline exposure per exclusion #
- •Anthracycline exposure exceeding a cumulative dose of 360 mg/m²
- •Known and ongoing HIV, Hepatitis B or Hepatitis C infection
- •Concomitant use of strong inhibitors of the liver microsomal enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A
- •Participation in concurrent study of an investigational agent or device
- •Any other condition including but not limited to major co-morbidities, which in the opinion of the investigator would render the patient ineligible
- •O2 Saturation by pulse oximetry at rest < 90%
- •Concomitant use of drugs that have significant risk of Torsades de Pointes will also be prohibited. Please refer to drugs listed under "Drugs with Risk of Torsades de Pointes"
研究组 & 干预措施
EPC2407 (crinobulin)
Experimental
干预措施: EPC2407 (crinobulin) (Drug)
结局指标
主要结局
Safety
时间窗: Duration of drug exposure
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT03309111Ichnos Sciences SA81
招募中
1 期
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaMultiple MyelomaPlasma Cell DisorderNCT04879043Heidelberg Pharma AG78
Unknown
1 期
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma PatientsRefractory Multiple MyelomaRecurrent Multiple MyelomaNCT03618602Shanghai Theorion Pharmaceutical Co Ltd.30
已完成
1 期
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)Advanced Solid TumorsNCT04882917EMD Serono Research & Development Institute, Inc.22
已完成
1 期
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy VolunteersHealthy ParticipantsNCT05117554Arcus Biosciences, Inc.70